Table 3 Key Indicators among pharmacies and private for-profit health facilities in PPM versus non-PPM districts

Any national first-line ACT (AL)

68.1

2.5

(59.7, 75.4)

(0.9, 6.8)

Chloroquine

63.6

96.7

(56.5, 70.2)

(92.3, 98.6)

N = 275

N = 110

Any confirmatory testing

72.6

12.1

(66.5, 78.0)

(6.6, 21.0)

Proportion of providers frwho:

N = 275

N = 110

Correctly state the national first-line treatment for uncomplicated P. falciparum/vivax malaria

65.0

(57.3, 72.0)

15.0

(7.6, 27.6)

Correctly state the first-line dosing regimen for uncomplicated P. falciparum/vivax malaria for an adult

51.0

(43.9, 58.0)

6.1

(2.7, 13.4)

N = 155

N = 36

Report receiving a supervisory or regulatory visit within the past year

74.5

(61.6, 84.3)

17.0

(4.1, 49.4)

Median price

Median

[IQR] ^{(N of Anti-malarials)}

Median

[IQR] ^{(N of Anti-malarials)}

National first-line ACT (AL) AETD #

$0.00

$0.00

[0.00–0.00] ⁽⁵¹⁶⁾

[0.00–0.00] ⁽³⁾

Chloroquine AETD #

$0.62

$0.62

[0.62–0.62] ⁽¹⁷³⁾

[0.47–0.62] ⁽¹⁰³⁾

Rapid diagnostic test

$0.00

$3.12

[0.00–0.25] ⁽²¹⁶⁾

[2.50–3.75] ⁽³⁸⁾